News

Two papers describe latest research in the PIRL

A long-term collaboration with Dr. Kevin Pinney and Dr. Mary Lynn Trawick of Baylor University has resulted in an exciting new therapeutic approach that exploits vascular disruption.

"We have shown that the water soluble phosphate pro-drug KGP 18 effectively causes selective vascular shutdown in breast and kidney tumors," says lead authors Dr. Ralph Mason and Dr. Li Liu. "Most significantly, it enhances the therapeutic growth delay in breast tumors when combined with carboplatin."

The study, "Imaging-Guided Evaluation of the Novel Small-Molecule Benzosuberene Tubulin-Binding Agent KGP265 as a Potential Therapeutic Agent for Cancer Treatment," was published Sept. 24, 2021, in Cancers.

In a related work, Dr. Mason presented a new software platform (RAFT) to effectively analyze multispectral optoacoustic data. The study, "A Scalable Open-Source MATLAB Toolbox for Reconstruction and Analysis of Multispectral Optoacoustic Tomography Data," was published Oct. 6, 2021, in Scientific Reports.